Amylyx Completes Patient Recruitment for Phase 2 Study Testing AMX0035 for ALS
Amylyx has completed patient recruitment for the Phase 2 clinical trial CENTAUR, which addresses the safety and effectiveness of AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS). In 2017, Amylyx launched…